POTOMAC, Md., May 28, 2024--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1
POTOMAC, Md., May 21, 2024--IGC Pharma to Attend BIO International Convention 2024
POTOMAC, Md., April 16, 2024--IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two.